A new AI model called popEVE can predict how likely each variant in a patient’s genome is to cause disease. The team is ...
Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study, sending its shares up over 15% in premarket trading. The drug, tinlarebant, ...
A study led by the Research Institute of the McGill University Health Center (The Institute) has identified a rare genetic ...
Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.
Disease development is often shaped by genetics, with how much or how little a gene is expressed influencing disease risk.
The first child in history has successfully been treated with a new genetic therapy for an ultra-rare developmental defect ...
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...
The parents of a three-year-old boy born with a devastating, life-limiting genetic condition say they are now excited for his ...
When you buy through links on our articles, Future and its syndication partners may earn a commission. Babies born with harlequin ichthyosis have very distinctive features, including platelike scales ...
A single, untargeted proteomics test for rare genetic diseases has been developed. A research team from the University of Melbourne (Australia) and Murdoch Children’s Research Institute (Victoria, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback